Future Journal of Pharmaceutical Sciences

Table 8 Results of %assay of tablet dosage form

From: A new stability indicating RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulation

Drug	Peak name	Peak area	Label claim	%assay
DOR	Standard	269,930	100	98.8
DOR	Test	267,191	100	98.8
LMV	Standard	1,247,416	300	98.7
LMV	Test	1,233,252	300	98.7
TDF	Standard	1,143,433	300	99.72
TDF	Test	1,141,431	300	99.72

DOR Doravirine, LAM Lamivudine, TDF Tenofovir disoproxil fumarate, % percentage

Back to article page